The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 9,593 | 18,100 |
| Depreciation and amortization | 5,838 | 10,756 |
| Share-based compensation expense | 4,356 | 8,414 |
| Provision for losses on accounts receivable | 1,206 | 1,904 |
| Change in deferred tax asset | 710 | - |
| Other | -155 | -430 |
| Accounts receivable | 13,180 | -1,587 |
| Inventories | 3,193 | 2,476 |
| Other current assets | -4,600 | 3,742 |
| Accounts payable | 17,397 | 3,751 |
| Accrued compensation | -1,350 | 2,864 |
| Other operating liabilities | 2,037 | -4,102 |
| Net cash provided by operating activities | 28,169 | 37,486 |
| Purchases of property and equipment | 5,207 | 10,111 |
| Payment for acquisitions | 4,001 | 8,920 |
| Other | 242 | 482 |
| Net cash used in investing activities | -8,966 | -18,549 |
| Proceeds from equity offering, net of underwriter fees | 0 | 29,039 |
| Payments for repurchase of common stock-Common Class A | 29,039 | - |
| Payments of equity offering costs | 0 | 1,594 |
| Repayment of notes payable | 497 | - |
| Repurchase of outstanding classa common stock | - | 29,039 |
| Principal payments on finance lease obligations | 1,117 | 2,276 |
| Contingent payments related to acquisitions | 309 | 1,950 |
| Contributions fromnon-controllinginterests | 390 | 1,229 |
| Distributions tonon-controllinginterests | 0 | 189 |
| Net cash provided by (used in) financing activities | -1,533 | -4,780 |
| Net change in cash and cash equivalents | 17,670 | 14,157 |
| Cash and cash equivalents at beginning of period | 4,660 | - |
| Cash and cash equivalents at end of period | 36,487 | - |
Guardian Pharmacy Services, Inc. (GRDN)
Guardian Pharmacy Services, Inc. (GRDN)